<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Clinical Trial Award | Assistant Professor level or above (or equivalent) | • **Preproposal submission is required; application submission is by invitation only.**  
   • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.  
   • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.  
   • Two options will be offered:  
     o **Planning Phase with Clinical Trial Option:** Provides support to prepare and submit an Investigational New Drug/Investigational Device Exemption (IND/IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded.  
     o **Clinical Trial Only Option:** Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission. | Clinical Trial:  
   • A funding limit is not defined; requested funding must be appropriate for the scope of work proposed.  
   • The maximum period of performance for the clinical trial is **4 years.**  
   **Planning Phase with Clinical Trial Option:**  
   • The maximum allowable funding for the Planning Phase period of performance is **$500,000** for direct costs.  
   • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
   • The maximum period of performance for the planning phase is **18 months.**  
   • The maximum period of performance for the clinical trial is **4 years.** | Pre-Application (Preproposal):  
   April 12, 2023  
   5:00 p.m. Eastern time  
   **Application:**  
   July 19, 2023  
   11:59 p.m. Eastern time |
| Discovery Award      | Postdoctoral fellow or clinical fellow (or equivalent) and above | • Supports the exploration of a highly innovative new concept or untested theory.  
   • Not intended to support the logical progression of an already established line of questioning.  
   • **Clinical trials will not be funded.** | Clinical Trial:  
   • The maximum allowable funding for the entire period of performance is **$200,000** for direct costs.  
   • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
   • The maximum period of performance is **2 years.** | Pre-Application (Letter of Intent):  
   March 29, 2023  
   5:00 p.m. Eastern time  
   **Application:**  
   April 26, 2023  
   11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Focused Program Award</strong></td>
<td>Full Professor level or above (or equivalent)</td>
<td>• Preproposal submission is required; application submission is by invitation only.</td>
<td>• The maximum allowable funding for the entire period of performance is $7.2 million for direct costs.</td>
<td>Pre-Application (Preproposal): April 12, 2023 5:00 p.m. Eastern time</td>
</tr>
<tr>
<td>Go to:</td>
<td></td>
<td>• Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.</td>
<td>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td>Application: July 19, 2023 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td><strong>Grants.gov Funding Opportunity</strong></td>
<td></td>
<td>• Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.</td>
<td>• The maximum period of performance is 4 years.</td>
<td></td>
</tr>
<tr>
<td>Number:</td>
<td>HT9425-23-PRMRP-FPA</td>
<td>• Projects may range from exploratory/hypothesis-developing studies through small-scale clinical trials that together will address the overarching goal/question.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator-Initiated Research Award</strong></td>
<td></td>
<td>• Research team of highly qualified, multidisciplinary project leaders should be led by an investigator with demonstrated success in directing large, focused projects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Go to:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Grants.gov Funding Opportunity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number:</td>
<td>HT9425-23-PRMRP-IIRA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator-Initiated Research Award</strong></td>
<td></td>
<td>• Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest.</td>
<td>The maximum allowable funding for the entire period of performance is $1.6 million for direct costs for single investigators and $2.0 million for partnering investigators.</td>
<td>Pre-Application (Letter of Intent): April 19, 2023 5:00 p.m. Eastern time</td>
</tr>
<tr>
<td>Go to:</td>
<td></td>
<td>• Partnering Principal Investigator Option available.</td>
<td>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td>Application: May 31, 2023 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical trials will not be funded.</td>
<td>• The maximum period of performance is 4 years.</td>
<td></td>
</tr>
<tr>
<td>Award Mechanism</td>
<td>Eligibility</td>
<td>Key Mechanism Elements</td>
<td>Funding</td>
<td>Submission Deadline</td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
</tbody>
</table>
| **Lifestyle and Behavioral Health Interventions Research Award** | Assistant Professor level or above (or equivalent)                           | • Supports the development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes.  
• Projects may include clinical research or clinical trials for interventions that do not require regulation by the FDA.  
• Encourages patient advocate participation in the research team.  
• Animal studies will not be funded.                                                                 | • The maximum allowable funding for the entire period of performance is **$3.0 million** for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years.           | Pre-Application (Letter of Intent): April 19, 2023  
5:00 p.m. Eastern time  
Application: May 31, 2023  
11:59 p.m. Eastern time |
| **Technology/Therapeutic Development Award**                | Assistant Professor level or above (or equivalent)                           | • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life.  
• Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.  
• Two funding levels are available depending on the maturity of the product. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:  
  o Funding Level 1: Supports research that is supported by significant preliminary data but has not advanced to the level of clinical translation.  
  o Funding Level 2: Supports research that is in the final states of preclinical development with potential for near-term clinical development. Applications must provide relevant data that support the rationale for the proposed study. Funding Level 2 recipients must submit or obtain an IND/IDE application to the FDA, or must transition the product to clinical practice, within the period of performance.  
• Clinical trials will not be funded.                      | Funding Level 1:  
• The maximum allowable funding for the entire period of performance is **$2.0 million** for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years.           | Pre-Application (Letter of Intent): April 19, 2023  
5:00 p.m. Eastern time  
Application: May 31, 2023  
11:59 p.m. Eastern time |

Grants.gov Funding Opportunity Number:  
HT9425-23-PRMRP-LBIRA  
HT9425-23-PRMRP-TTDA